Molecular and Cellular Biology

A01  MicroRNA regulation of oral squamous cell carcinoma. Gary Guishan Xiao1,2, Thomas Dobleman2. 1School of Pharmaceutic Science and Technology, Dalian University of Technology, Dalian, China, 2Creighton University School of Medicine, Omaha, USA.

A02  Autophagy regulates lactate shuttle and resistance to oxidative stress of ovarian cancer-associated fibroblasts. Qian Wang1,2, Liang Xue3, Xiaoyu Zhang3, Shixia Bu1, Xueliang Zhu1, Dongmei Lai1. 1International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200030, P. R. China, 2Institute of Embryo-Fetal Original Adult Disease Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200030, P. R. China, 3Institute of Biochemistry and Cell Biology, SIBS, Chinese Academy of Sciences, Shanghai 200031, P.R. China.

A03  Diagnostic applications of new hepatoma carcinoma cell aptamers in vitro. Fei Ding. Jianghan University, Wuhan, China.

A04  The decreased serum dopamine level is associated with poor prognosis in non-small cell lung cancer and contributes to cancer cell stemness. Xiaoyuan Wu, Wei Zhao Central lab, Nanjing Chest Hospital, Nanjing, Jiangsu Province, China.

A05  Isoform-specific regulation of AKT turn-motif phosphorylation and overall phosphorylation profiles. Huifang Guo1, Sean Barnes1, Shanshan Bai2, Meng Gao3, Qinghua Yu1, Yiling Lu1, Ji Yong Liang1, Philip L. Lorenzi3, Eric Jonasch2, Gordon B. Mills1, Zhiyong Ding1. Departments of 1Systems Biology, 2Genitourinary Medical Oncology, and 3Bioinformatics & Computational Biology, UT MD Anderson Cancer Center, Holcombe Blvd, Houston, USA.

A06  NDRG2 modulates the differentiation of mice intestinal epithelial cells. Yongzheng Ma, Libo Yao, and Jian Zhang. State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, The Fourth Military Medical University, Xi’an, China.

A07  The novel protective role of P27 in MLN4924-treated gastric cancer cells. Jie Liu, Qi Zhang, and Dongqin Yang. Fudan University, Shanghai, China.
**New Horizons in Cancer Research: Bringing Cancer Discovery to Patients**

November 12–15, 2015 • Shanghai Marriott Parkview Hotel • Shanghai, P.R. China

**Poster Session A - Friday, November 13, 2015, 1:00-3:30 p.m.**

**Tumor Biology**

**A08** Hepatocellular carcinoma repression by TNFα-mediated synergistic lethal effect of senescence and apoptosis sensitization. Dan Li1, Jing Fu2, Min Du3, Haibin Zhang2, Lu Li1, Jin Cen1, Weiyun Li1, Xiaotao Chen1, Edward M. Conway4, Eli Pikarsky5, Hongyan Wang3, Yuan Ji5*, Hong-Yang Wang2 and Lijian Hui1. 1State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China; 2Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China; 3Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China; 4Centre for Blood Research, Division of Hematology-Oncology, Department of Medicine, University of British Columbia, Vancouver, Canada; 5Department of Immunology and Cancer Research, Institute for Medical Research Israel Canada, and Department of Pathology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

**A09** Osteopontin involves cisplatin resistance and poor prognosis in oral squamous cell carcinoma. Tai-Jan Chiu1,2,3. 1Division of Hematology-Oncoology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niasong District, Kaohsiung 833, Taiwan, 2Kaohsiung Chang Gung Head and Neck Oncology Group, Cancer Center, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niasong District, Kaohsiung 833, Taiwan, 3Institute of Clinical Medical Sciences, Chang Gung University, Kaohsiung 833, Taiwan.

**A10** The increased serum norepinephrine is associated with poor prognosis in non-small cell lung cancer and contributes to cancer cell metastasis. Wei Zhao, and Xiaoyuan Wu. Central lab, Nanjing Chest Hospital, Guangzhou Rd. No.215, Gulou, Nanjing, Jiangsu, China.

**A11** Human DCTPP1 modulates drug sensitivity to 5-fluorouracil through epigenetically regulating MDR1 expression in gastric cancer cell line BGC-823. Li-liang Xia1,2,3, Fei-fei Song2, Ling Xu4, Hong-ying Zhu4, Ping Ji2, Yong Zhang2, Guo-ping Zhao1,2, Ying Wang2,3, 1Department of Microbiology and Microbial Engineering, School of Life Sciences, Fudan University, Shanghai, China; 2Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiaotong University School of Medicine, Shanghai, China; 3Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai, Shanghai, China; 4Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.

**A12** FASN, ErbB2-mediated glycolysis is required for breast cancer cell migration. Lan Zhou, Sufang Jiang, Hua Li, Kailing Tu, Kaicheng Wang, Qiang Fu, and Yuhua Zhao. West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan, People’s Republic of China.

**A13** New tumor suppressor NDRG2 increased colorectal cancer cells to 5-Fluorouracil through regulating Nr2-ROS pathway. Ruohan Zhang, Jian Zhang. State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, The Fourth Military Medical University, Xi’an, China.

A15 Metapristone reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells A549. Hongning Chen, Guirong Zhen, Jian Liu, Jie Wang, Yusheng Lu, Ning Zhen, C. Yan, Ting Chi, X. Yu, J. Ma, Yingying Xiao, Jingwei Shao, L. Jia. Cancer Metastasis Alert and Prevention Center, College of Chemistry; Biopharmaceutical photocatalysis, State Key Laboratory of Photocatalysis on Energy and Environment, Fuzhou University, Fuzhou, China.


A17 NDRG4 hypermethylation at the CpG island is associated with the risk of gastric adenocarcinoma. Xiaoying Chen1, Qingxiao Hong1, Yan Xu1, Jieer Ying2, and Shiwei Duan1. 1School of Medicine, Ningbo University, Ningbo, Zhejiang, China; 2Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.

A18 MiR-129-3p promotes Docetaxel resistance of breast cancer cells via CP110 inhibition. Yuan Zhang, Yu Wang, Yifang Wei, Meningyang Li, Mingxiang Ye, Suning Chen, Wenchao Liu, Jian Zhang. The Fourth Military Medical University, Xi’an, China.

A19 Combination of Rapamycin with whey protein concentration suppresses trastuzumab-resistant breast cancer cell stemness by down-regulating Nrf2. Li-Yu Tsai, Shih-Hsuan Cheng. Department of Medical Laboratory Science and Biotechnology, College of Health Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan.

A20 Similarities between embryo implantation and circulating tumor cells adhesion to human umbilical vein endothelial cells. XiaoBo Yu, Qing Shi, Jian Liu, Yusheng Lu, Ting Chi, Yajun Liu, Jingwei Shao, Lee Jia*. Cancer Metastasis Alert and Prevention Center, and Biopharmaceutical Photocatalysis of State Key Laboratory of Photocatalysis on Energy and Environment, College of Chemistry, Fuzhou University, Fuzhou, China.
Cyclophilin B causes chemotherapeutic resistance in colon cancer. Tae Gyu Choi and Sung Soo Kim. Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul, Republic of Korea.

MicroRNA-7 inhibits the stemness of prostate cancer stem-like cells and tumorigenesis by suppressing KLF4/PI3K/Akt/p21 pathway. Yun-Li Chang, Pei-Jie Zhou, Lianzi Wei, Wang Li, Zhongzhong Ji, Yu-Xiang Fang, Wei-Qiang Gao. State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; School of Biomedical Engineering & Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China; Collaborative Innovation Center of Systems Biomedicine, Shanghai, China.

Dexamethasone inhibits non-small cell lung cancer growth in vitro and in vivo: involvement of inactivation of estrogen via the induction of estrogen sulfotransferase. Lijie Wang, Wei Lu, Tianyan Zhou. Department of Pharmaceutics, School of Pharmaceutical sciences, Peking University, Beijing, China; State Key Laboratory of Natural and Biomimetic Drugs (Peking University), Beijing, China.

miR-486-5p plays as tumour suppressor by targeting CDK4 in non-small cell lung cancer. Yang Shao, Yuqing Shen, Bingjie Zhang, Youxin Jin, Zhongliang Ma. School of Life Sciences, Shanghai University, Shanghai, China.

The Interplay of size and surface functionality on the cellular uptake of sub-10 nm gold nanoparticles. Shuaidong Huo, Ying Jiang, Vincent M. Rotello, Xingjie Liang. National Center for Nanoscience and Technology, Beijing, China; Department of Chemistry, University of Massachusetts-Amherst, USA.


A28 Nanocytological assessment of liver field carcinogenesis for prediction of future hepatocellular carcinogenesis. Hemant K. Roy¹, Hariharan Subramanian², Richard Kalman¹, Andrew Starz², David Nunes¹, Vadim Backman². ¹Boston Medical Center 650 Albany Street Suite 526 Boston, MA, USA; ²Northwestern University Biomedical Engineering 2145 Sheridan Road Evanston, IL, USA.

A29 Determining prostate cancer aggressiveness utilizing a novel DNA methylation approach. Kamilla Mundbjerg¹, Sameer Chopra¹, Mehrdad Alemozaffar¹, Peter W. Nichols², Manju Aron², Kimberly D. Siegmund¹, Osamu Ukimura¹, Peter A. Jones¹, Inderbir Gill¹, and Gangning Liang¹. ¹Department of Urology, ²Department of Pathology, ³Department of Preventive Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA; ⁴Van Andel Research Institute, Grand Rapids, MI, USA.

Clinical Trials

A30 A Phase IIb, single-arm, biomarker stratified, prospective, double-blinded, multicenter clinical trial to assess the efficacy of hepatic arterial infusion of cisplatin and 5-fluorouracil in patients with advanced hepatocellular carcinoma Who have failed sorafenib treatment. Jung-Hee Kwon¹, Moo-Sang Kim¹, Jin Young Park¹, Yun Suk Yu¹, Si Hyun Bae², Hee Jung Wang³. ¹CbsBioscience Inc., Daejeon, Korea; ²Department of Internal Medicine, the Catholic University of Korea, Seoul, Korea; ³Department of Surgery, Ajou University School of Medicine, Suwon, Korea.

Epidemiology

A31 Interaction between processed meat intake and NAT2 for risk of colorectal cancer in Japanese and African Americans. Hansong Wang¹, Motoki Iwasaki², Christopher A. Haiman³, Suminori Kono⁴, Temitope O. Keku⁵, Robert S. Sandler⁶, Sonja I. Berndt⁶, Shoichiro Tsugane⁷, Loïc Le Marchand¹. ¹University of Hawaii Cancer Center, Honolulu, HI, ²Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan, ³Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, ⁴Department of Preventive Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ⁵Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, NC, ⁶Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Experimental and Molecular Therapeutics

A32 EPS8 as a new anticancer target in acute myeloid leukemia and a peptide inhibitor derived from the EGFR binding region of EPS8. Tong-yuan Xue¹, Yi-ran Chen², Yi-bo He², Yu-hua Li³. ¹Department of Hematology, Zhujiang Hospital, Southern Medical University, China ²Second School of Clinical Medicine, Southern Medical University, China.

New Horizons in Cancer Research: Bringing Cancer Discovery to Patients
November 12–15, 2015 • Shanghai Marriott Parkview Hotel • Shanghai, P.R. China
Poster Session A - Friday, November 13, 2015, 1:00-3:30 p.m.

A34 Drug resistant murine tumor models facilitate development of next generation anticancer therapeutics. Ying Jing, Juan Zhang, Lan Zhang, Dandan Zhu, Yanmei Sun, Guanping Mao, Minxia Wang, Qian Shi*. Crown Bioscience, Inc., China.

A35 Prediction of cancer patient responses to different treatments using personalized tumor models or models with matching genomic profiles. Jingjing Jiang¹, Ying Yan¹, Zhongguang Luo², Jia He³, Tengfei Yu¹, Wei Du¹, Xuqin Yang¹, J Gu¹, L Hua¹, XK Ye¹, Jie Liu² and Zhenyu Gu¹. ¹GenenDesign, Shanghai, China, ²Huashan Hospital, Fudan University, Shanghai, China, ³Peking Union Medical College Hospital, Beijing, China.

A36 Molecular mechanisms of arginine-auxotrophic response in arginine-starvation therapy. Macus Tien Kuo, Wen-Bin Tsai, Yan Long. Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

A37 The combined use of two non-anticancer drugs, Sulpiride and Dexamethasone, in the treatment of drug-resistant and metastatic breast cancer. Jian Li, Liang Li, Wei Lu, Tianyan Zhou. Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, China.

A38 Inactivation of SIRT7 interferes metabolism and reverses proliferation phenotypes in oral tongue squamous cell carcinoma by up-regulating ROS. Min Zheng, Li Li, Jing Xu. Department of Stomatology, Zhoushan Hospital, Zhoushan, Zhejiang, China.

A39 Combination of dopamine and axitinib shows synergistic efficacy in the treatment of drug-resistant breast cancer. Yuanheng Ma, Siyuan Wang, Jian Li, Fangran Hao, Wei Lu, Tianyan Zhou. Department of Pharmaceutics, School of Pharmaceutical sciences, Peking University, Beijing, China.

A40 In vitro and in vivo evaluation of the antitumor efficiency of Lx2-32c against prostate cancer. Guangyao Lv, Xiaoxia Xie, Weishuo Fang, Fenghua Fu, Hongbo Wang. Key Laboratory of Molecular Pharmacology and Drug Evaluation (Ministry of Education), Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, China.

A41 The study of a novel Sorafenib derivative JW-09 as an antitumor agent. Jingwen Zhang, Zeyu Yao, Jiawen Yao, Fenghua Fu, Hongbo Wang. Key Laboratory of Molecular Pharmacology and Drug Evaluation (Ministry of Education), Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai, China.

A42 SB-365 isolated from Pulsatilla koreana has anti-tumor activity through promoting apoptosis and inhibiting migration in brain tumor cells. Joo Han Lim, Mi Soon Kim, In Suh Park, Kyung Hee Jung, Moon Hee Lee, Soon Sun Hong. Inha University School of Medicine, Incheon, South Korea.
A43  **BRAF mutants evade ERK dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition.** Zhan Yao¹, Neilawattie M. Torres¹, Anthony Tao⁶, Yijun Gao⁷, Lusong Luo³, Qi Li², Elisa de Stanchina⁴, Omar Abdel-Wahab²⁴, David B. Solit²⁴, Poulikos Poulakakos⁵ and Neal Rosen¹². ¹Program in Molecular Pharmacology, ²Department of Medicine, ³Human Oncology and Pathogenesis Program, and ⁴Center for Molecular Oncology, Memorial Sloan-Kettering Cancer Center, New York, USA; ⁵Icahn School of Medicine at Mount Sinai, New York, USA; ⁶Center for Neural Science, College of Arts and Sciences, New York University, New York, USA; ⁷BeiGene (Beijing) Co., Ltd., No.30 Science Park Road, Zhong-Guan-Cun Life Science Park, Changping District, Beijing, P.R.China.

Immunology

A44  **Immunotherapy with patient-specific antigens selection relieved the metastasis of a cervical cancer patient.** Yanyan Han¹³, Jianting Long³, Sheng Ye², Ran Tao³, and Xiangjun Zhou³. ¹State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; ²Cell Immunotherapy Center, Dept. of Medicinal Oncology, the First Affiliated Hospital of SUN Yat-Sen University, Guangzhou, China. ³SYZ Cell Therapy Co., Shenzhen, China.

A45  **Immunological characterization: allograft of primary murine breast cancer (MuPrimeTM) versus murine breast cancer cell derived syngeneic tumors.** Bin Chen, Yunfei Wu, Qiaofang Yan, Likun Zhang, Davy Ouyang, Zhun Wang, Jie Cai, and Henry QX Li. Crown Bioscience (Taicang) Inc. No 6 Beijing West Road, Taicang Jiangsu Province, P.R. China.

Prevention Research

A46  **Gender difference in risk factors for colorectal cancer with colorectal polyps.** Shigeru Hirota¹, Satoko Yamaguchi¹, Tomofumi Ooizumi¹, Kensuke Asakura¹, Keinosuke Abe¹, Tatsuyori Shozushima¹, Yoshke Toya¹, Nozomi Matsuda¹, Kazumitsu Tomita¹, Kunihiko Sato¹, Takashi Kosaka¹, Risaburo Akasaka¹, Shunichi Yanai¹, Keisuke Kawasaki¹, Sho Shibata¹, Yukido Abiko¹, Norihiko Kudara¹, Shuhei Oana¹, Masaki Endo¹, Toshimi Chiba¹, Shotaro Nakamura¹, Noriyuki Uesugi², Kazuyuki Ishida³, Tamotsu Sugai³, Takayuki Matsumoto¹. ¹Iwate Medical University, Department of Internal Medicine, Division of Gastroenterology, Akita, Japan, ²Iwate Medical University, Department of Molecular Diagnostic Pathology, Akita, Japan,
Experimental and Molecular Therapeutics

A47 Effects of folinic acid, 5-FU and oxaliplatin-based preoperative chemotherapy on BIRC7/Livin expression in human colorectal cancer cells in Zaria, Nigeria. Mohammed Faruk1*, Adamu Abdullahi2, Ahmed Adamu3, Surajo Mohammed Aminu4, Sani Ibrahim5, Yawale Iliyasu1, Atara Ntekim6, Abdullahi Jubril Randawa7, John Idoko1, Khalid Zahir Shah8. 1Department of Pathology, Ahmadu Bello University Teaching Hospital, Nigeria; 2Department of Radiotherapy and Oncology, Ahmadu Bello University Teaching Hospital, Nigeria; 3Department of Surgery, Ahmadu Bello University Teaching Hospital, Nigeria; 4Department of Haematology and Blood Transfusion, Ahmadu Bello University Teaching Hospital, Nigeria; 5Department of Biochemistry, Ahmadu Bello University, Nigeria; 6Department of Radiation Oncology, University College Hospital Ibadan, Nigeria; 7Department of Obstetrics and Gynaecology, Ahmadu Bello University Teaching Hospital Zaria, Nigeria; 8Department of Biomedical Science, University of Wolverhampton, UK.

A48 ZLM-7 a novel combretastatin A4 analogue induces impairment of endothelial cells function and inhibits angiogenesis by inhibiting VEGFR pathway. Min Su, Xiyuan Qin, Kunjian Peng, Zhiyong Luo. Molecular Biology Research Center, State Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, China.


Clinical Research (Not including clinical trials)

A50 Preoperative prognostic nutritional index predicts survival after curative resection for hepatocellular carcinoma. Yunpeng Hua1, Fei Ji2, Shunjun Fu3, Shunli Shen1, Shaoqiang Li1, Lijian Liang3, baogan Peng1. 1Department of hepatic Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; 2Department of Organ Transplant Center, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Tumor Biology

A51 Lentivirus mediated silence of Homeo Box C6 (HOXC6) prevent cell malignant proliferation in colorectal cancer cell via autophagy pathway. Meiling Ji, W.T. Tang, Q.Y. Feng, L.L. Yang, Y.X. Lao, D.X. Zhu, Q. Lin, P.P. Xu, P.Zheng, Jianmin Xu*. Zhongshan Hospital, Fudan University, Department of General Surgery, Shanghai, China.

Molecular and Cellular Biology

A52 PIK3CA mutational analysis platform utilizing the Labcyte Echo® Liquid Handler to reduce cost, sample amount and increase throughput to broadly assess acquired mutational status. Charline Hsieh, John Lesnick and Linda Orren. Labcyte, Borregas Avenue Sunnyvale, California, USA.
Tumor Biology

A53  Combining kinetic ligand binding and 3D tumor invasion technologies to assess drug residence time and anti-metastatic effects of CXCR4 inhibitors. Brad Larson1, Leonie Rieger1, Nicolas Pierre2, Hilary Sherman3. 1BioTek Instruments, Inc., Winooski, VT, 2Cisbio US, Inc., Bedford, MA, 3Corning Incorporated, Life Sciences, Kennebunk, ME.

A54  Quantification of MMP activity and inhibition in a 3D tumor invasion model. Brad Larson1, Leonie Rieger1, Diana Hulboy2 and Crystal Falco2. 1BioTek Instruments, Inc., Winooski, VT, 2Enzium, Philadelphia, PA.

Prevention Research

A57  Screening of endophytic fungi inhibiting lung cancer cell growth and angiogenesis from mangrove in Zhanjiang. Xin Liu1, Xiaowei Feng1, Wenzhang Zhang1, Liu Fei1, Xudong Tang1,2,*. 1Institute of Biochemistry and Molecular Biology, 2Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Guangdong Medical University, Zhanjiang, Guangdong, China.

Epidemiology

A58  A clinical model for early recognition of pancreatic cancer. Qiang Nai1, Jing Liu2, Ping Zhang3, Yozsef Duhl3, Shuvendu Sen1, Abdalla Yousif4. 1RBMC, Perth Amboy, NJ, USA; 2Shandong University, Jinan, China.

A59  Small intestine angiosarcoma: Case report and literature review. Qiang Nai1, Jing Liu2, Rafey Khan1, Xin Liu, Hadi Razjouyan3, Arkady Broder4, Yozsef Dhul3, Shuvendu Sen1, Abdalla Yousif4. 1Raritan Bay Medical Center, Perth Ambou, NJ, USA; 2School of Public Health, Shandong University, Jinan, China. 3Saint Peter’s University Hospital, New Brunswick, NJ USA 08901. 4Duke University Medical Center, Durham, NC, USA.

A61  Association of pathogenic mutations in BRCA2 exon 11 with early onset breast cancer in Sri Lankan population. Sumadee De Silva1, Kamani Tennekoon1, Aravinda Dissanayake2, Kanishka De Silva2, Lakshika Jayasekara3, Vahnipriya Manoharan1. 1Institute of Biochemistry, Molecular Biology and Biotechnology, 90, Cumaratunga Munidasa Mawatha, Colombo 03, Sri Lanka, 2National Cancer Institute, Maharagama, Sri Lanka.

Molecular and Cellular Biology

A62  Targeting interference of Golgi protein 73 gene on the liver cancer cell in invasion and metastasis. Ying Yang, Dilireba-Bolidong, and Yongxing Bao. Department of Cancer Center, The First Affiliated Hospital of XinJiang Medical University, Urumqi, China.
Clinical Trials

A63 Transarterial ethanol ablation for portal vein tumor thrombus using cone beam computed tomography. Biao-yang, Zheng-yin Liao. Department of Abdominal Oncology, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.

Molecular and Cellular Biology

A64 Cofactor ff Brca1 as a modulator of hepatocellular carcinoma growth and migration. Eman El Zeneini\textsuperscript{1}, Asma Amleh\textsuperscript{1,2}.\textsuperscript{1} Biotechnology Department, American University in Cairo, New Cairo, Egypt; \textsuperscript{2} Biology Department, American University in Cairo, New Cairo, Egypt.

A65 Cdk3-mediated colon cancer metastasis through epithelial-mesenchymal transition. Jinping Lu, Damao Huang, Shan Zhou, and Faqing Tang. Clinical Laboratory and Medical Research Center, Zhuhai Hospital of Jinan University, Zhuhai, Guangdong.

A66 \textit{Helicobacter pylori} CagA promotes gastric cancer cell proliferation with FUT4/LeY overexpression through EGFR/MAPKs signaling pathway. Faisal Aziz\textsuperscript{1}, Xiaqi Wang\textsuperscript{2}, and Yan Qiu\textsuperscript{1}.\textsuperscript{1} Department of Biochemistry and Molecular Biology, Dalian Medical University, Liaoning Provincial Core Lab of Glycobiology and Glycoengineering, Dalian, China; \textsuperscript{2} Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, USA.

Experimental and Molecular Therapeutics

A67 \#2714, a novel active inhibitor with potent arrested G2/M phase and antitumor efficacy in preclinical models. You-Zhi Xu\textsuperscript{1,3}, Wen-jie Lu\textsuperscript{2,3}, Li-xin Kan\textsuperscript{1}, Si-ying Wang\textsuperscript{1}, Sheng-yong Yang\textsuperscript{3}, Ying-Lan Zhao\textsuperscript{1}.\textsuperscript{1} Department of Pathophysiology, Basic Medical College, Anhui Medical University, Hefei, China; \textsuperscript{2} Department of Pharmacology, Basic Medical College, Anhui Medical University, Hefei, China; \textsuperscript{3} State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.

A68 Recombinant soluble gp130 protein reduces DEN-induced primary hepatocellular carcinoma in mice. Hang Wang, Guoying Shen, Da Lin, Yanxue Lin, Jing Hong, Nahui Ye, Yashan Guo, Chengjun Deng\textsuperscript{*}, Chun Meng. Institute of Pharmaceutical Biotechnology and Engineering, College of Biological Science and Biotechnology, Fuzhou University, Fuzhou, Fujian, China.

Molecular and Cellular Biology

A69 AMPK\textsubscript{\alpha}2 deficiency enhanced the tumor-associated macrophage polarization through AMPK\textsubscript{\alpha}1 activation caused by tumor-induced energy deprivation. Shulan Qiu, Beijing AnZhen. Hospital, Capital Medical University; Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, People’s Republic of China.
A70  The proteome of prostate cancer. Diego Iglesias-Gato\textsuperscript{1,2,3}, Pernilla Wikström\textsuperscript{4}, Charlotte Lavallee\textsuperscript{1,2,3}, Anders Bergh\textsuperscript{5}, Tamar Geiger\textsuperscript{6}, Matthias Mann\textsuperscript{5} and Amilcar Flores-Morales\textsuperscript{1,2,3}.
\textsuperscript{1}Molecular Disease Biology Section, IVS, Faculty of Health Sciences. University of Copenhagen. Copenhagen, Denmark. \textsuperscript{2}Novo Nordisk Research Foundation Centre for Protein Research, Faculty of Health Sciences, University of Copenhagen. Copenhagen, Denmark. \textsuperscript{3}Danish Cancer Society. Copenhagen. Denmark. \textsuperscript{4}Department of Medical Biosciences, Pathology, Umea University, Umea, Sweden. \textsuperscript{5}Department of Proteomics and Signal Transduction, Max Planck Institute for Biochemistry, Martinsried, Germany.

Clinical Research (Not including clinical trials)

A71  One case report of male primary urothelium carcinoma and literature review. Qiang Dang, Huijian Zhang, Yang Luo, Di Gu, Yaodong Jiang, Peng Wu, Shaobin Zheng. Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

A72  Perioperative blood pressure is associated with long-term survival in rectal cancer patients. Huichuan Yu, Jianping Wang, and Yanxin Luo. The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.

A74  The genetic susceptibility to pediatric embryonal brain tumor: A report from Han population. Baocheng Wang, and Jie Ma. Xinhua Hospital, Shanghai, China.

Immunology

A75  Mannosylated poly (propylene imine) dendrimer mediated lung delivery of anticancer bioactive. Saurabh Bhargava\textsuperscript{1}, Vishal Bhargava\textsuperscript{2}, Gomed Agarwal\textsuperscript{3}. \textsuperscript{1}Manav Bharti Univ., \textsuperscript{2}KRV hospitals, \textsuperscript{3}KRV hospitals pvt. ltd. India.
Molecular and Cellular Biology

**B01** Tailoring approaches for global epigenome analysis from archival formalin-fixed paraffin-embedded tissue samples. Sudipto Das¹, Bruce Moran¹, Rut Klinger¹, Bozena Fender³, Gillian Peutman¹, Dominiek Smets², Annette Byrne¹, Matthias Ebert⁵, Diether Lambrechts⁵, William M. Gallagher¹,³, Darran O’Connor¹.¹Cancer Biology & Therapeutics Laboratory, UCD Conway Institute, University College Dublin, Ireland, ²Department of Translational Genetics, VIB, K.U. Leuven, Belgium, ³OncoMark Ltd., Nova UCD, Ireland, ⁴Department of Physiology, RCS1, Ireland, ⁵University of Heidelberg, Manheim, Germany.

**B02** DNA methylation-dependent transcription regulatory networks elucidate dynamics of transcription regulatory circuitry in cancers. Xuerui Yang, Zhengtao Xiao, Yang liu, Yu Liu. Tsinghua University, Beijing, China.

**B03** Establishment of three-dimensional primary tumor cell culture method and novel drug sensitivity test. Hiroshi Goji¹, Manami Shimomura¹, Yasushi Uemura¹, Tetsuya Nakatsura¹, M.Mamunur Rahman¹, Manabu Itoh¹, Denis Liu⁴. ¹SCIVAX Life Sciences, Inc., Kawasaki, Kanagawa, Japan, ²Division of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center; Kashiwa, Chiba, Japan, ³SCIVAX USA, Woburn, MA, USA, ⁴Life Sciences Division, JSR(Shanghai)Co. Ltd. China.

**B04** Hepatitis C virus core protein interacts with snail and histone deactylases to promote the metastasis of hepatocellular carcinoma. Dan Nie, Xiaoliang Shan, Lizhu Nie, Yujie Duan, Zhen Chen, Zhi Li, Ling Tian, Qingzh Gao, Ni Tang. The Second Affiliated Hospital and the Key Laboratory of Molecular Biology for Infectious Diseases designated by the Chinese Ministry of Education, Chongqing Medical University, Chongqing, China.

**B05** Aberrant expression of mesoderm-specific transcript homolog protein (MEST) in lung cancer promotes invasion and metastasis. Bin Li, Yang Wang, Ru-Yuan Yu, Qing-Yu He. Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University, Guangzhou, China.

**B06** Overexpression of Survivin in non-small cell lung cancer via epigenetic silencing of miR-203. Shuiliang Wang¹, Ling Zhu¹, Weimin Zuo¹, Zhiyong Zeng², Lianghu Huang¹, Fengjin Lin¹, Rong Lin¹, Jin Wang¹, Jun Lu¹, Qinghua Wang¹, Lingjing Lin¹, Huiyue Dong¹, Weizhen Wu¹, Kai Zheng¹, Jinquan Cai¹, Shunliang Yang¹, Yujie Ma³, Shixin Ye³, Wei Liu³, Yinghao Yu³, Jianming Tan³, and Bolin Liu⁴. ¹Fujian Key Laboratory of Transplant Biology, ²Department of Thoracic Surgery, ³Department of Pathology, Fuzhou General Hospital, Xiamen University, Fuzhou, Fujian, China; ⁴Department of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

**B07** PTK7 biphasically regulates the KDR activity in endothelial cells and angiogenesis. Won-Sik Shin, Hye-Won Na, and Seung-Taek Lee. Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea.
New Horizons in Cancer Research: Bringing Cancer Discovery to Patients
November 12–15, 2015 • Shanghai Marriott Parkview Hotel • Shanghai, P.R. China
Poster Session B – Saturday, November 14, 2015, 12:00-2:30 p.m.

B08 Analysis for the cleavage of syndecan2 by matrix metalloproteinase 14. Young Hun Lee1, Minju Pyo1, Jun Hyyoung Park2, Dong Huey Cheon2, Sojoong Choi3, Jun Sang Park2, Taeyoung Kim1, Eok-Soo Oh1, Ji Eun Lee1, and Seung-Taek Lee1. 1Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea, 2Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea, and 3Department of Life Sciences and the Research Center for Cellular Homeostasis, Ewha Womans University, Seoul, Republic of Korea.

Tumor Biology

B09 The early genetic events in cervical cancers of chinese women and their implications in cancer immunotherapy. Xia Li1, Haijiang Huang1, Chen-Yi He1, Ming Qi4, Zhi-Ying Chen1. 1Laboratory for Gene and Cell Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, P.R. China, 2Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA, 3Broad Institute of MIT and Harvard, 4BGI-Shenzhen, Shenzhen, P.R. China.

B10 PSGL-1 deficiency Promotes Intestinal Tumor Growth in Mice by Up-regulation Chemokine Ligand 9 and PSGL-1 Clinic Significance. Jiangchao Li1, Zeqi Zhou1, Zheng Li1, Xiaohan Zhang1, Dan He2, Yuxiang Ye1, Qianqian Zhang1, Cuiling Qi1, Xiaodong He1, Chen Yu1, Chunkui Shao2, Liang Qiao3. 1Vascular Biology Research Institute, Guangdong Pharmaceutical University, Guangzhou, China; 2Department of Department of Pathology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. 3Storr Liver Centre, Westmead Millennium Institute for Medical Research, the University of Sydney at the Westmead, NSW 2145, Australia. 4Department of gastroenterology, The Third Affiliated Hospital of Pharmaceutical University, Guangzhou, China.

B11 Functions and mechanisms of metapristone in triple-negative breast cancer cells. Cuicui Yan, Suhong He, Xingtian Yang, Jian Liu, Ji Ma, S. Yu*, Lee Jia*. Cancer Metastasis Alert and Prevention Center, College of Chemistry, Fuzhou University, Fuzhou, China.

B12 Metapristone inhibits cell adhesion with reversal of epithelial-mesenchymal transition in MDA-MB-231 breast cancer cells. Xingtian Yang, Jia Lee*, Sudan He, Cuicui Yan, Suhong Yu*. Cancer Metastasis Alert and Prevention Center, College of Chemistry, Fuzhou University, Fuzhou, China.

B13 Inhibition of Prostate Cancer Invasion and Metastasis by the Combination of Docetaxel and Aneustat via Targeting EZH2. Sifeng Qu1,2, Francesco Crea1,2, Dong Lin1,2, Colin C. Collins2,4, Peter W. Gout3, Yuzhuo Wang1,2,3,4. 1Department of Experimental Therapeutics, BC Cancer Research Centre, Vancouver, BC, Canada; 2Vancouver Prostate Centre, Vancouver, BC, Canada; 3Interdisciplinary Oncology Program, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; 4Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.

New Horizons in Cancer Research: Bringing Cancer Discovery to Patients
November 12–15, 2015 • Shanghai Marriott Parkview Hotel • Shanghai, P.R. China
Poster Session B – Saturday, November 14, 2015, 12:00-2:30 p.m.

B15 Toward evidence-based precision oncology for metastatic castrate resistant prostate cancer by combining cell free DNA and functional characterization of mutations. Colin C Collins1,3, Nada Lallous3, Stanislav Volik3, Brian McConeghy3, Sonal Brahmbhatt3, Anne Haegert3, Kevin Beja1, Bob Shukin1, Shannon Awrey3, Eric LeBlanc3, Ronnie Tse1, Josef Murillo1, Arun Azad1,2, Alexander Wyatt1,3, Stéphane LeBihan1, Yuzhou Wang1,2, Kim Chi1,2,3, Martin Gleave1,3, Paul S. Rennie1, and Artem Cherkasov1,3. 1Vancouver Prostate Centre, Vancouver, British Columbia, Canada. 2Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. 3University of British Columbia, Vancouver, British Columbia, Canada.

B16 Mitochondrial dynamics modify metastatic potential from PDAC. Meifang Yu, Jason Fleming, Eugene Koay, and Cullen Mitsuo Taniguchi. UT MD Anderson, USA.

B17 Down-regulation of BEX1 inhibits the proliferation of colorectal cancer through JNK/c-jun pathway. Yeting Hu1,2, Qian Xiao1,2, Haiyan Chen1,2, Yue Liu1,2, Zhanhuai Wang1,2, Xiangfeng Shen1,2, Qi Yang1,2, Kefeng Ding1,2. 1The Key Laboratory of Cancer Prevention and Intervention of China National Ministry of Education, The Key Laboratory of Molecular Biology in Medical Sciences of Zhejiang Province, Cancer Institute, Hangzhou, Zhejiang, China; 2Department of Surgical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

B18 Role for alkaline ceramidases and bioactive sphingolipids in non-melanoma skin cancer. Chih-Li Lin, Ruijuan Xu, and Cungui Mao. Departments of Medicine, Stony Brook Cancer Center, and Department of Dermatology at Stony Brook University, Stony Brook, New York, USA.

B19 Two faces of YAP: Oncogene in malignant progression but barrier for phenotypic transition in LKB1-deficient lung cancer. Wenjing Zhang, Yijun Gao, Xiangkun Han, Fuming Li, Hongbin Ji. Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.

B20 Cdc42 as the essential effector for regional difference of mouse lung cancer risks. Yuetong Wang, and Hongbin Ji. Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sc, Shanghai, China.

B21 PTK7 enhances FGF-mediated signaling pathways in esophageal squamous cell carcinoma cells. Won-Sik Shin, Yong-Hun Choi, and Seung-Taek Lee. Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Korea.

B22 FBW7α and GSK3β-mediated Mcl-1 ubiquitination and degradation are pro-apoptotic mechanisms and therapeutic approaches to overcome resistance to target therapies in cancer. Mingxiang Ye1,2,3, Nan Li1, Xinxin Zhang1, Ning Chang1, Jian Zhang1. 1Department of Pulmonary Medicine, Xijing Hospital, Xi’an, China; 2Department of Biochemistry and Molecular Biology; 3State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi’an, China.

Carcinogenesis

B23 Overexpression of AJUBA enhances cell motility of esophageal squamous cell carcinoma. Xuejiao Shi, Yibo Gao, Mei Luo, Zengmiao Sun, Chengcheng Zhou, Zitong Li, Wenhui Yang, Yuan Li, Jingnan Wang, Zhaoli Chen and Jie He. Department of Thoracic Surgery, Cancer Institute and Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
New Horizons in Cancer Research: Bringing Cancer Discovery to Patients
November 12–15, 2015 • Shanghai Marriott Parkview Hotel • Shanghai, P.R. China
Poster Session B – Saturday, November 14, 2015, 12:00-2:30 p.m.

B24 Mediator subunit MED23 supports hepatocellular carcinoma development via metabolism regulation. Lihua Min, Zhichao Wang, Yajing Chu, Xiao Yao, Ke Li, and Gang Wang. State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yue Yang Rd., Shanghai, China.

B25 The impact of hr-HPV infection on the survival and immunoresponse of patients with esophageal squamous cell carcinoma. Dianrong Zhou, Weiwei Zheng, Guangzhou Gao, Yulin Sun, Fang Liu, Lanning Zhou, Shuyang Dai, Yuanyuan Qiao, Xiaohang Zhao. State Key Laboratory of Molecular Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Center for Basic Medical Science, Navy General Hospital, Beijing, China; Graduate School of Southern Medical University, Guangzhou, China.

Cancer Chemistry


B27 Ursolic acid-Aspirin conjugates potently prevents cancer metastasis both in vitro and in vivo. Qiao Tang, Yajun Liu, Tao Li, Ting Chi, Jian Liu, Xiaobo Yu, Jingwei Shao, Lee Jia. Cancer Metastasis Alert and Prevention Center, College of Chemistry, Fuzhou University, Fuzhou, China.

Clinical Research (Not including clinical trials)


B29 A gene signature for predicting prognosis in patients with colorectal cancer. Yong Hwa Jo, Minh Nam Nguyen, Tae Gyu Choi and Sung Soo Kim. Department of Biochemistry and Molecular Biology, Medical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, School of Medicine, Kyung Hee University, Seoul, Republic of Korea.

Epidemiology

B30 Diabetes and kidney cancer risk in patients with type 2 diabetes: a retrospective cohort analysis of the National Health Insurance. Chin-Hsiao Tseng. Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan; Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
New Horizons in Cancer Research: Bringing Cancer Discovery to Patients
November 12–15, 2015 • Shanghai Marriott Parkview Hotel • Shanghai, P.R. China
Poster Session B – Saturday, November 14, 2015, 12:00-2:30 p.m.

B31 Peanut: A protector against esophageal squamous cell carcinoma in a high risk area, China.
Qing-Kun Song1, Jun Ren2, Lin Zhao2, Yu-Chen Li1, Jiang-Ping Wu1, Jun Li1. 1Beijing Key Laboratory of Therapeutic Cancer Vaccine, Beijing Shijitan Hospital, Capital Medical University, 2Xuanwu Hospital, Capital Medical University, 3Yanting Cancer Hospital.

Experimental and Molecular Therapeutics

B32 Radioprotection of IDH1-mutated solid tumor, but not leukemia cells by the IDH1-mutant inhibitor AGI-5198. Remco J. Molenaar1, Johanna W. Wilmink2, Jaroslaw P. Maciejewski3, William P. Leenders4, Fonnet E. Bleeke5, Cornelis J. van Noorden1. 1Department of Cell Biology & Histology, Academic Medical Center, University of Amsterdam, The Netherlands; 2Department of Medical Oncology, Academic Medical Center, University of Amsterdam, The Netherlands; 3Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA; 4Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands; 5Department of Clinical Genetics, Academic Medical Center, University of Amsterdam, The Netherlands.

B33 Mechanistic elucidation of the antitumor properties of benzyl isothiocyanate in breast cancer. Bei Xei1, 3, Arumugam Nagalingam1, Neeraj K. Saxena2, and Dipali Sharma1. 1Department of Oncology, Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore; 2Department of Medicine, University of Maryland School of Medicine, Baltimore, USA; 3Key laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medicinal Sciences, Lanzhou University, Lanzhou, China.

B34 The synergistic antitumor effect of the combination of oncolytic herpes simplex virus HF10 and monoclonal antibody Bevacizumab against human breast carcinoma xenograft. Gewen Tan1, 4, Hideki Kasuya1, Tevfik Tolga Sahin1, Kazuo Yamamura4, Zhiwen Wu1, Yusuke Koide4, Yoshihiro Hotta5, Toshio Shikano5, Suguru Yamada5, Akiyuki Kanzaki5, Tsutomu Fujii6, Hiroyuki Sugimoto5, Shuji Nomoto5, Yoko Nishikawa5, Maki Tanaka4, Naoko Tsurumaru1, Toshihiko Kuwahara4, Saori Fukuda1, Toyone Kikumori5, Weiqiang You5, Nengquan Sheng6, Yi Yang7, Jianfeng Gong4, Jun Yan4, Zhigang Wang4, Shin Takeda1, Akimasa Nakao1, Yasuhiro Kodera1. 1Department of Surgery II, Nagoya University Graduate School of Medicine, Nagoya, Japan; 2TAKARA BIO INC., Otsu, Shiga, Japan; 3Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; 4Department of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China.

B35 MiR-145 inhibits cell growth in colon carcinoma by targeting p21 activated kinase 4 and LIMK1-confilin pathway. Gewen Tan, Weiqiang You, Nengquan Sheng, Yi Yang, Jianfeng Gong, Jun Yan, Zhigang Wang. Department of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China.

B36 The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. Jikui Guan. Gothenburg University, Medicinaregatan 9A, Box 440, 40530 Gothenburg, Sweden.
**New Horizons in Cancer Research: Bringing Cancer Discovery to Patients**

November 12–15, 2015 • Shanghai Marriott Parkview Hotel • Shanghai, P.R. China

*Poster Session B – Saturday, November 14, 2015, 12:00-2:30 p.m.*

**B37** Alpha5-nicotinic acetylcholine receptor mediates the anti-apoptotic activity of nicotine induced by cisplatin in gastric cancer. Yanfei Jia, Xiaoli Ma*. Central Laboratory, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.

**B38** Systematic analysis of drug sensitivity caused by tumor suppressor loss. Xiaoxi Li, Hongyu Ding, and Hai Jiang. Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.

**B39** p53 regulates inhibition of neurogenesis after irradiation. Shun Wong¹, Yuqing Li², Zoey Cheng³. ¹University of Toronto, Canada, ²Sunnybrook Health Sciences Centre, Canada.

**B40** Metabolic profiling of a small molecule modulator of tumor suppressor microRNA-34a in human and mouse liver microsomes. Yangchao Chen¹,². ¹School of Biomedical Sciences, Faculty of Medicine, the Chinese University of Hong Kong; ²Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China.

**B41** A persistently activated signaling network regulates the stromal DNA damage secretory program to promote cancer resistance. Boyi Zhang¹, Fei Chen¹, Paul Chiao³ and Yu Sun¹,²,³,⁴*. ¹Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences; Shanghai Jiaotong University, School of Medicine, Shanghai, China; ²Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; ³VA Seattle Medical Center, Seattle, WA, USA 98108; ⁴Department of Medicine, University of Washington, Seattle, WA, USA.


**Immunology**

**B43** Eradication of B cell tumors by minicircle DNA-mediated CD20/CD3 bispecific antibody production. Xiao-Juan Pang¹,², Fei Ma¹,², Pei-Fa Zhang¹,², Jing Zhang¹,², Yu-Jian Zhong¹, Yi Hou¹,², Tian-Yan Wang¹, Gang Zheng¹, Cheng-Yi He¹, Zhi-Ying Chen¹. ¹Laboratory for Gene and Cell Engineering, Chinese Academy of Sciences Shenzhen Institute of Advanced Technology, Shenzhen, Guangdong, China. ²Department of Research, Hornetcon Biotechnology Company, Shenzhen, Guangdong, China. ³Laboratory of perinatal center and Genetic Metabolism, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.

**B44** Enhancement of cancer-specific cytotoxicity of T cells using a bispecific antibody-based technology. Fei Ma¹,²,³, Xiao-Juan Pang¹,², Pei-Fa Zhang¹,², Zhong-Sheng Wang¹,²,³, Jing Zhang¹, Gang Zheng¹, Yu-Jian Zhong¹, Yun-Hong Liu¹, Cheng-Yi He¹, Xin Xiao², Zhi-Ying Chen¹. ¹Laboratory for Gene and Cell Engineering, Chinese Academy of Sciences Shenzhen Institute of Advanced Technology, Shenzhen, Guangdong, China. ²Laboratory of perinatal center and Genetic Metabolism, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China. ³Department of Research, Hornetcon Biotechnology Company, Shenzhen, Guangdong, China.
B45  MMSA-1 is a potential antigen candidate for the immunotherapy of multiple myeloma. Shan Meng¹, Chenyang Lu¹, Wenjun Shen², Yongchang Wei³, Dan Su¹, Xingmei Cao¹, Aili He³, Wanggang Zhang¹, Fuling Zhou¹. ¹Department of Clinical Hematology, Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an, Shaanxi Province, P.R.China, ²Division of Endocrinology, Gerontology and Metabolism, School of Medicine, Stanford University, Stanford, CA, USA, ³Department of Clinical Oncology, The First Affiliated Hospital, College of Medicine of Xi’an Jiaotong University, Xi’an, Shaanxi Province, P.R.China.

Molecular and Cellular Biology

B46  Regulation of global protein serine/threonine dephosphorylation in cancer cells by OLA1, an Obg-like NTPase. Dong Xu¹,², Renduo Song¹, Prince Jeyabal¹, Amanda M. Weiskoff¹, and Zheng-Zheng Shi¹. ¹Department of Translational Imaging, Houston Methodist Research Institute, Weill Cornell Medical College, Houston, Texas, United States, ²Department of Surgical Oncology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, China.

Experimental and Molecular Therapeutics

B47  Hyaluronic acid coated paclitaxel nanocrystal formulation (HA-PTX) showed improved targeted delivery, anti-tumor efficacy with reduced toxicity (PTX is a kind gift from Dabur Pharmaceuticals). Jyotsana Singh, Shweta Sharma, Ashwini Verma, Prabhat Ranjan Mishra and Rituraj Konwar. Division of Endocrinology, Central Drug Research Institute, India.

B48  Establishment of humanized PD-1 mouse model for in vivo pharmacological evaluation of anti-human PD-1 antibodies. Zhun Wang¹, Bin Cai², Gang Chen², Jinping Liu¹, Annie Xiaoyu An¹, Davy Xuesong Ouyang¹, Jean Pierre Wery¹, Jay Liu³, Xin Dong³, Henry Qixiang Li¹. ¹Crown Bioscience, Inc., 3375 Scott Blvd, suite 108, Santa Clara, CA. ²Nanjing Galaxy Biopharmaceutical Co. Ltd., 12 Xuefu Rd., Gaoxin District, Nanjing, Jiangsu, China.

Clinical Trials

**B50** Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR inhibitors. Xu Qing\(^1\), Ji Yun Lee\(^2\), Wei Xiumin\(^2\), Bai Yali\(^2\), **Jee Sanga**\(^3\), So Hyeon Bak\(^4\), Ho Yun Lee\(^5\), Jong-Mu Sun\(^5\), Se-Hoon Lee\(^5\), Jin Seok Ahn\(^5\), Eun Kyung Cho\(^6\), Dong-Wan Kim\(^7\), Hye Ryun Kim\(^8\), Young Joo Min\(^9\), Sin-Ho Jung\(^1\), Keunchil Park\(^1\), Myung-Ju Ahn\(^*\), Mao Mao\(^2\). \(^{1}\)Division of Hematology-Oncology, Department of Medicine, \(^{2}\)Translational Bioscience and Diagnostics, WuXi AppTec, Waigaoqiao Free Trade Zone, Shanghai, China, \(^{3}\)Department of Biostatistics and Bioinformatics, \(^{4}\)Department of Radiology, Kangwon National University Hospital, Chuncheon, Korea, \(^{5}\)Department of Radiology, Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, \(^{6}\)Division of Hematology-Oncology, Department of Medicine, Gachon Medical School, Gil Medical Center, Incheon, Korea, \(^{7}\)Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, \(^{8}\)Division of Oncology, Department of Medicine, Yonsei University College of Medicine, Seoul, Korea, \(^{9}\)Department of Oncology, Asan Medical Center, University of Ulsan college of Medicine, Seoul, Korea.

Cancer Chemistry

**B51** Characterization of pluripotent and lineage-specific biomarkers in high-grade serous ovarian carcinoma amongst treatment-naïve and neoadjuvant chemotherapy-treated tumors. Tarra Evans\(^1\), Brooke Howitt\(^2\), Kyle Strickland\(^2\), Christopher Crum\(^3\), Ross Berkowitz\(^1\), and **Shu-Wing Ng**\(^1\). \(^1\)Laboratory of Gynecologic Oncology, Division of Gynecologic Oncology; \(^2\)Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Tumor Biology

**B52** Overexpression of human papillomavirus type 16 oncoproteins enhances epithelial-mesenchymal transition via STAT3 signaling pathway in non-small cell lung cancer cells. Xudong Tang\(^1\), Yun Feng\(^1\), Wenzhang Zhang\(^1\), Xin Liu\(^1\), Fei Liu\(^1\). \(^1\)Institute of Biochemistry and Molecular Biology, \(^2\)Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Guangdong Medical University, Zhanjiang, Guangdong, China.

**B53** Bioenergetic adaptation by metastatic cancer cells to reduce the unrequired bioenergy in emergencies. Yusheng Lu\(^1\), Shu Lian\(^1\), Yunlong Cheng\(^2\), Min-Liang Kuo\(^2\), Haiyan Liang\(^1\), Lee Jia\(^1\). \(^1\)Cancer Metastasis Alert and Prevention Center, \(^2\)and Biopharmaceutical Photocatalysis of State Key Laboratory of Photocatalysis on Energy and Environment, College of Chemistry, Fuzhou University, Fuzhou, China. \(^4\)Graduate Institute of Biochemical Sciences, College of Life Science, National Taiwan University, No. 1, Section 4, Roosevelt Road, Taipei 106, Taiwan.
Molecular and Cellular Biology

B54  S-nitrosocaptopril inhibits expression of cell adhesion molecules via regulating NF-κB signal pathway. Shu Lian¹, Yusheng Lu¹, Min-Liang Kuo², Alan Yueh-Luen Lee³, Ting Yu¹, Haiyang Liang¹, Yunlong Cheng¹, Lee Jia¹. ¹Cancer Metastasis Alert and Prevention Center, and Biopharmaceutical Photocatalysis of State Key Laboratory of Photocatalysis on Energy and Environment, College of Chemistry, Fuzhou University, Fuzhou, China, ²Graduate Institute of Biochemical Sciences, College of Life Science, National Taiwan University, Taipei, Taiwan, ³National Institute of Cancer Research, National Health Research Institutes, Zhunan, Miaoli, Taiwan.

Experimental and Molecular Therapeutics

B55  A novel and specific c-MET TKI is highly efficacious against a cohort of xenograft tumors derived from selected NSCLC and HCC patients. Dawei Chen, Mengmeng Yang, Juan Zhang, Boyu Zhong, Zhenjian Du, Guizhong Liu, Qian Shi, Joe Shih, Jean Pierre Wery, Henry Qixiang Li. Crown Bioscience, Inc., China.

Prevention Research

B56  The effect of ginseng on the pharmacological function of warfarin in rats. Ji Ma, Tao Li, Hongning Chen, Cuicui Yan, Yingying Xiao, Lee Jia*. Cancer Metastasis Alert and Prevention Center, College of Chemistry; Biopharmaceutical photocatalysis, State Key Laboratory of Photocatalysis on Energy and Environment, Fuzhou University, Fuzhou, China.

Tumor Biology

B57  Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites and development of Multi Risk Score (MRS) formula. Iole Maria Di Gangi,¹ Tommaso Mazza,² Andrea Fontana,³ Massimiliano Copetti,³ Caterina Fusilli,² Antonio Ippolito,² Fulvio Mattivi,² Anna Latiano,³ Angelo Andriulli,⁴ Urska Vrhovsek¹ and Valerio Pazienza⁴. ¹Department of Food Quality and Nutrition, Research and Innovation Centre, Fondazione Edmund Mach (FEM) San Michele all'Adige, Italy; ²Unit of Bioinformatics, I.R.C.C.S. “Casa Sollievo della Sofferenza” Hospital San Giovanni Rotondo (FG) Italy; ³Unit of Biostatistics I.R.C.C.S. “Casa Sollievo della Sofferenza” Hospital San Giovanni Rotondo (FG) Italy; ⁴Gastroenterology Unit, I.R.C.C.S. “Casa Sollievo della Sofferenza” Hospital San Giovanni Rotondo (FG) Italy.
Experimental and Molecular Therapeutics

B58 Suppression of cdc37 induces bortezomib resistance through autophagy activation and plasma cell immaturation in multiple myeloma. Meiromg Zang PhD, Fengyan Jin MD, Lanting Liu, Gang An MD, Xiaqi Qin MD, Xiaoyan Feng MD, Yan Xu MD, Mu Hao PhD, Wen Zhou PhD, Wen Zhou PhD. 1State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China. 2Cancer Research Institute, Central South University; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education; Key Laboratory of Carcinogenesis, National Health and Family Planning Commission, Hunan, China. 3Cancer Center, The First Hospital of Jilin University, Changchun, China.

B59 A driver role for ZEB1 in EGFR TKI resistance of lung cancer cells. Lixia Guo, Ting Zhang, Yanan Yang. 1Thoracic Disease Research Unit, Division of Pulmonary and Critical Care Medicine; Department of Biochemistry and Molecular Biology; 2Cancer Center and College of Medicine, Mayo Clinic, Rochester, USA.

Tumor Biology

B60 Engineered resistant modified diet (ERMD) inhibits tumor growth in in vitro and in vivo pancreatic cancer models. Valentina Andrulli Buccheri, Kaarel Adamberg, Chiara Saracino, Signe Adamberg, Madis Jaagura, Concetta Panebianco, Raivo Vailu, and Valerio Pazienza. 1Gastroenterology Unit, I.R.C.C.S. “Casa Sollievo della Sofferenza” Hospital San Giovanni Rotondo (FG) Italy; 2Department of Food Processing Tallinn University of Technology; 3Competence Center of Food and Fermentation Technologies, Estonia; 4Department of Chemistry Tallinn University of Technology, Estonia.

Experimental and Molecular Therapeutics

B61 The distribution of UGT2B7 genetic polymorphisms and the influence on valproic acid pharmacokinetics epilepsy patients in Chinese island. Yinxiang Sun, Jinping Lu, and Faqing Tang. Clinical Laboratory and Medical Research Center, Zhuhai Hospital of Jinan University, Zhuhai, Guangdong.

Prevention Research


Cancer Chemistry

B63 Diagnostic value of serum cathepsin B and D in patients with nasopharyngeal carcinoma. Gongjun Tan, Jinping Lu, Yuejin Li, and Faqing Tang. Medical Research Center, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan, P.R. China.
B64  Plasma mRNA expression levels as potential predictive biomarkers for chemotherapy in gastric cancer. Jie Shen, Jia Wei, Baorui Liu. The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, China.

Tumor Biology

B65  Upregulated long non-coding RNA AFAP1-AS1 expression is associated with progression and poor prognosis of nasopharyngeal carcinoma and other cancers. Hao Bo, Zhaojian Gong, Wenling Zhang, Xiayu Li, Lei Shi, Yu Lian, Yizhou Jing, Zheng Li, Yanhong Zhou, Guiyuan Li, Wei Xiong, Zhaoyang Zeng. The Key Laboratory of Carcinogenesis of the Chinese Ministry of Health and The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, The Central South University, Changsha, Hunan, China.

Experimental and Molecular Therapeutics

B66  S-equol, a secondary metabolite of natural anticancer isoflavone daidzein, inhibits prostate cancer growth in vitro and in vivo, through activating the Akt/FOXO3a pathway. Zongliang Lu1,2, Rui Zhou1,2,3, Ya Kong1, Jiajia Wang1, Wanyuan Xia1, Jian Yang1, Hongxia Xu1. 1Department of Nutrition, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing, China; 2Research Center for Nutrition and Food Safety, Third Military Medical University, Chongqing, China.

Carcinogenesis

B67  Dietary compound isoliquiritigenin prevents mammary carcinogenesis by targeting GRP78 in breast cancer stem cells. Zhiyu Wang1, Neng Wang2, Pengxi Liu1, Jianping Chen3. 1Department of Mammary Disease, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Medical Collage, Guangzhou University of Traditional Chinese Medicine, Guangdong, China; 2Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China; 3School of Chinese Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong.

Tumor Biology

B68  The pathological(IHC) characters and clinical manifestations of extramammary scrotum paget’s disease. Qiang Dang, Huijian Zhang, Yang Luo, Di Gu, Yaodong Jiang, Peng Wu, Shaobin Zheng. Department of Urology, Nanfang Hospital, Southern Medical University, China.

B69  The essential role of ARF in tumor microenvironment during prostate cancer progression. Yingqiu Xie1, Wenfu Lu2, Qing Yang2, Brett S. Carver3, Zhenbang Chen2. 1Department of Biology, School of Science and Technology, Nazarbayev University, Astana, Kazakhstan. 2Department of Biochemistry and Cancer Biology, Meharry Medical College, Nashville, USA. 3Department of Surgery and Division of Urology, Memorial Sloan-Kettering Cancer Center, New York, USA.
New Horizons in Cancer Research: Bringing Cancer Discovery to Patients
November 12–15, 2015 • Shanghai Marriott Parkview Hotel • Shanghai, P.R. China
Poster Session B – Saturday, November 14, 2015, 12:00-2:30 p.m.

B70 Molecular mechanism of colorectal cancer through the perspective of endogenous network dynamics. Ruoshi Yuan¹, Jiekai Yu², Yanqin Huang³, Suzhan Zhang², Shu Zheng², Xiaomei Zhu³, Ping Ao³. ¹Key Laboratory of Systems Biomedicine, Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, 200240, China, ²Key Laboratory of Cancer Prevention and Intervention, Chinese Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Hangzhou, Zhejiang Province, 310009, China, ³GeneMath, 5525 27th Ave. N.E., Seattle, WA 98105, USA.

Cancer Chemistry

B71 Intracranial juvenile xanthogranuloma in children: A report of four cases and review of the literature. Baocheng Wang. Xinhua hospital, affiliated to Shanghai Jiaotong University, Shanghai, China.

Experimental and Molecular Therapeutics

B72 The gelatinases-stimuli nanoparticles reverse docetaxel resistance and epithelial to mesenchymal transition in lung cancer cell line. Qin Liu, Ru-Tian Li, Bao-Rui Liu. The Comprehensive Cancer Center of Drum-Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, P.R. China.

B73 Anti cancer effect of Moringa root extract in OAW 42 (ovarian cancer) cell line. Chinmoy Bose. NCRI, Park Lane.

Molecular and Cellular Biology

B74 Association of DNA repair gene X-ray repair cross-complementation group 1 (XRCC1 Arg399Gln and Arg280His) to develop Oesophageal Carcinoma in the Northeast India. Snigdha Saikia¹,², Prajyalendra Barooah¹,², Mallika Bhattacharyya², Bhabdev Goswami², Manab Deka², Subhash Medhi¹. ¹Department of Applied Science, Gauhati University, Gopinath Bordoloi Nagar, Guwahati, Assam, India, ²Department of Gastroenterology, Gauhati Medical College and Hospital, Guwahati, Assam, India.

Cancer Chemistry

B75 Intratumoral lactic acidosis is a key target for clinical cancer therapy. Ming Chao¹, Hao Wu², Kai Jin¹, Bin Li¹, Jian-jun Wu¹, Guangqiang Zhang², Qiangrong Pan², Xun Hu². ¹Department of Radiology, ²Cancer Institute (a Key Laboratory For Cancer Prevention & Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, China.